SS Innovations International Inc. (NASDAQ: SSII) has reported record second-quarter revenue of $13.9 million, a 39.4% increase year over year, as demand for its SSi Mantra surgical robotic system continues to surge. The company's first-half revenue reached $25.0 million, up 65.6% from the same period in 2025, signaling robust commercial momentum.
The company's growth is primarily driven by system installations. During the quarter, SSi Mantra installations rose 30.4% to 30 systems, bringing the total installed base to 224 systems across 12 countries. Cumulative surgeries performed using the platform reached 12,272, underscoring its clinical adoption and reliability.
Gross profit for the second quarter increased 20.0% to $7.1 million, though gross margin declined to 50.9% from 59.1% in the prior-year quarter. For the first half, gross profit rose 77.5% to $12.4 million, with an improved gross margin compared to the first half of 2025 (https://nnw.fm/zxrT1).
Looking ahead, regulatory milestones could serve as significant catalysts. The company is targeting FDA clearance by the first quarter of 2027 and EU CE marking by the end of 2026. Achieving these approvals would open up the large U.S. and European markets, potentially accelerating revenue growth beyond current levels.
Additionally, SS Innovations' telesurgery achievements are expanding the clinical profile of the SSi Mantra platform, demonstrating its capabilities in remote surgery and enhancing its value proposition. While system installations remain the primary commercial growth driver, telesurgery adds a differentiating factor that could attract new customers and partnerships.
The company's performance reflects a growing demand for minimally invasive surgical robotics, a market projected to expand significantly in the coming years. SS Innovations' focus on affordability and accessibility positions it well to compete with established players, particularly in emerging markets where cost-effective robotic systems are in high demand.
Investors and industry observers will be watching closely as the company progresses toward regulatory approvals and continues to expand its global footprint. With the installed base growing and surgeries accumulating, SS Innovations is building a solid foundation for long-term success. The record revenue and strong pipeline suggest that the company is on a trajectory to capitalize on the increasing adoption of robotic-assisted surgery worldwide.
